HansBiomed Corporation (KOSDAQ: A042520)
Health Care · Biotechnology · KR
₩17,010.00
-19.19% today · +124.4% 1Y
HansBiomed Corporation (KOSDAQ: A042520) operates in the Biotechnology industry within the Health Care sector. The company is valued at $175.04M.
Over the last twelve months the share price has gained 124.4%, trading between 6.97K and 57.80K.
Tweenvest scores HansBiomed Corporation across four factors: quality 47/100, value 68/100, growth 51/100. Its strongest factor is value.
A042520 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $175.04M
- Revenue (TTM)
- $80.60M
- P/E
- —
- EPS
- -1,432.07
- Dividend yield
- —
- Beta (5Y)
- 1.99
- 52-week high
- ₩57,800.00
- 52-week low
- ₩6,970.00
- Avg volume (3M)
- —
- Shares outstanding
- 14.26M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.